BridgeBio doses first participant in ASCEND-ATTR Phase 3b/4 study
BridgeBio said the first participant was dosed in its Phase 3b/4 ASCEND-ATTR study evaluating acoramidis on disease regression in ATTR-CM.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
BridgeBio announces first participant dosed in ASCEND-ATTR
BridgeBio said the first participant has been dosed in ASCEND-ATTR, a Phase 3b/4 study evaluating the long-term effects of acoramidis on disease regression in ATTR-CM.